Terms: = Lung cancer AND BCL9, LGS, 607, ENSG00000116128, MGC131591 AND Treatment
65 results:
1. Primary treatment Modification and treatment Tolerability Among Older Chemotherapy Recipients With Advanced cancer.
Mohamed MR; Rich DQ; Seplaki C; Lund JL; Flannery M; Culakova E; Magnuson A; Wells M; Tylock R; Mohile SG
JAMA Netw Open; 2024 Feb; 7(2):e2356106. PubMed ID: 38358742
[TBL] [Abstract] [Full Text] [Related]
2. Economic evaluation of serplulimab plus chemotherapy as the first-line treatment of oesophageal squamous cell carcinoma in China.
Chen F; Long Y; Yang J; Zhong K; Liu B
BMJ Open; 2023 Dec; 13(12):e078924. PubMed ID: 38149425
[TBL] [Abstract] [Full Text] [Related]
3. Assessing health-related quality of life among cancer survivors during systemic and radiation therapy in Bangladesh: a cancer-specific exploration.
Shahjalal M; Sultana M; Gow J; Hoque ME; Mistry SK; Hossain A; Mahumud RA
BMC Cancer; 2023 Dec; 23(1):1208. PubMed ID: 38062438
[TBL] [Abstract] [Full Text] [Related]
4. Multi-classification model incorporating radiomics and clinic-radiological features for predicting invasiveness and differentiation of pulmonary adenocarcinoma nodules.
Sun H; Zhang C; Ouyang A; Dai Z; Song P; Yao J
Biomed Eng Online; 2023 Nov; 22(1):112. PubMed ID: 38037082
[TBL] [Abstract] [Full Text] [Related]
5. Network Pharmacology-Based Identification of Key Pharmacological Mechanism of Shen-qi-di-huang Decoction Acting on Uremia.
Zhang X; Chen XF; Chen WJ; Ding H; Zhang BX
Altern Ther Health Med; 2024 Jan; 30(1):44-50. PubMed ID: 37773677
[TBL] [Abstract] [Full Text] [Related]
6. First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial.
Özgüroğlu M; Kilickap S; Sezer A; Gümüş M; Bondarenko I; Gogishvili M; Nechaeva M; Schenker M; Cicin I; Ho GF; Kulyaba Y; Zyuhal K; Scheusan RI; Garassino MC; He X; Kaul M; Okoye E; Li Y; Li S; Pouliot JF; Seebach F; Lowy I; Gullo G; Rietschel P
Lancet Oncol; 2023 Sep; 24(9):989-1001. PubMed ID: 37591293
[TBL] [Abstract] [Full Text] [Related]
7. Variation in treatment Charges and Reimbursement Among Individual Thoracic Surgeons.
Mitzman B; Wang X; Haaland B; Varghese TK
Ann Thorac Surg; 2024 Mar; 117(3):645-650. PubMed ID: 37479124
[TBL] [Abstract] [Full Text] [Related]
8. Risk profiles and a concise prediction model for lymph node metastasis in patients with lung adenocarcinoma.
Liang S; Huang YY; Liu X; Wu LL; Hu Y; Ma G
J Cardiothorac Surg; 2023 Jun; 18(1):195. PubMed ID: 37340322
[TBL] [Abstract] [Full Text] [Related]
9. Clinical features of CDK4/6 inhibitor-related interstitial lung disease in patients with breast cancer: a case series study.
Funasaka C; Naito Y; Kusuhara S; Nakao T; Nakajima H; Kawamoto M; Baba K; Mamishin K; Kondoh C; Harano K; Matsubara N; Hosono A; Sasaki T; Kawasaki T; Mukohara T
Jpn J Clin Oncol; 2023 Jan; 53(2):105-114. PubMed ID: 36373891
[TBL] [Abstract] [Full Text] [Related]
10. EGFR testing in paraffin-embedded cell block cytology material is reliable with increased detection for effusion fluid.
Man Ng JK; Chow C; Kin Chan RC; Pang Chan K; Xi Li JJ; Ching Li MS; To KF
Lung Cancer; 2022 Dec; 174():97-103. PubMed ID: 36356494
[TBL] [Abstract] [Full Text] [Related]
11. SNP rs9387478 at ROS1-DCBLD1 Locus is Significantly Associated with lung cancer Risk and Poor Survival in Indian Population.
Chongtham J; Pandey N; Sharma LK; Mohan A; Srivastava T
Asian Pac J Cancer Prev; 2022 Oct; 23(10):3553-3561. PubMed ID: 36308382
[TBL] [Abstract] [Full Text] [Related]
12. The cost-effectiveness of brigatinib in adult patients with ALK inhibitor-naive ALK-positive non-small cell lung cancer from a US perspective.
Cranmer H; Kearns I; Young M; Humphries MJ; Trueman D
J Manag Care Spec Pharm; 2022 Sep; 28(9):970-979. PubMed ID: 36001099
[No Abstract] [Full Text] [Related]
13. Repurposing clofazimine for malignant pleural mesothelioma treatment - In-vitro assessment of efficacy and mechanism of action.
Parvathaneni V; Chilamakuri R; Kulkarni NS; Wang X; Agarwal S; Gupta V
Life Sci; 2022 Oct; 306():120843. PubMed ID: 35908620
[TBL] [Abstract] [Full Text] [Related]
14. Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line treatment of Advanced Non-small Cell lung cancer With Programmed Death-Ligand 1 Expression ≥50.
Kuznik A; Smare C; Chen CI; Venkatachalam M; Keeping S; Atsou K; Xu Y; Wilson F; Guyot P; Chan K; Glowienka E; Konidaris G
Value Health; 2022 Feb; 25(2):203-214. PubMed ID: 35094793
[TBL] [Abstract] [Full Text] [Related]
15. RYR2 mutation in non-small cell lung cancer prolongs survival via down-regulation of DKK1 and up-regulation of GS1-115G20.1: A weighted gene Co-expression network analysis and risk prognostic models.
Ren W; Li Y; Chen X; Hu S; Cheng W; Cao Y; Gao J; Chen X; Xiong D; Li H; Wang P
IET Syst Biol; 2022 Apr; 16(2):43-58. PubMed ID: 34877784
[TBL] [Abstract] [Full Text] [Related]
16. Survival outcome of pulmonary metastasectomy among the patients with colorectal cancers.
Yıldız O; Dae SA; Fındıkcıoglu A; Kose F
Rev Assoc Med Bras (1992); 2021 Jul; 67(7):1015-1020. PubMed ID: 34817516
[TBL] [Abstract] [Full Text] [Related]
17. Afatinib treatment in a large real-world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation.
Huang CH; Ju JS; Chiu TH; Huang AC; Tung PH; Wang CC; Liu CY; Chung FT; Fang YF; Guo YK; Kuo CS; Yang CT
Int J Cancer; 2022 Feb; 150(4):626-635. PubMed ID: 34558665
[TBL] [Abstract] [Full Text] [Related]
18. Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma.
Liu Z; Williams M; Stewart J; Glisson BS; Fuller C; Roy-Chowdhuri S
Cancer Cytopathol; 2022 Feb; 130(2):110-119. PubMed ID: 34375025
[TBL] [Abstract] [Full Text] [Related]
19. [Current status of postoperative pathological diagnosis of lung cancer in China: a multicenter big data study].
;
Zhonghua Bing Li Xue Za Zhi; 2021 Aug; 50(8):882-890. PubMed ID: 34344071
[No Abstract] [Full Text] [Related]
20. Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell lung cancer in the US.
Wang Y; Rui M; Yang L; Wang X; Shang Y; Ma A; Li H
Front Public Health; 2021; 9():650392. PubMed ID: 33889559
[No Abstract] [Full Text] [Related]
[Next]
